An innovative pilot study at Be Well Hospital in Chennai, India, has revealed the extraordinary potential of Nichi-BRITE Beta glucans to transform the landscape of Parkinson’s disease treatment. These exceptional food supplements, sourced from the AFO-202 strain of Aureobasidium Pullulans, led to marked enhancements in patients’ Unified Parkinson’s Disease Rating Scale (UPDRS) and constipation scores after a 90-day regimen.
Parkinson’s disease, a debilitating neurological disorder, affects millions of individuals across the globe. Groundbreaking research is increasingly highlighting the vital link between gut health and neurological conditions like Parkinson’s. Nichi-BRITE Beta glucans exhibit the remarkable ability to regulate harmful gut bacteria while promoting the growth of beneficial microbiota.
Dr. Dedeepiya, a co-author of the study, conveyed enthusiasm for Nichi-BRITE’s potential as an adjunct therapy for synucleinopathies, such as Parkinson’s disease and multiple system atrophy. Dr. Nithyanandam, the study’s neurologist, stressed the need for more extensive investigations to uncover the full extent of Nichi-BRITE’s capabilities.
During a World Parkinson’s Day webinar, Prof. Muralidhar Hegde from Houston Methodist Research, USA, expounded on the critical role of alpha-synuclein abnormalities in the development of neurodegenerative diseases. Dr. Rukmini Mridula from Hyderabad brought attention to the growing incidence of young-onset Parkinson’s disease cases in India.
The inspiring results from this pilot study suggest that Nichi-BRITE Beta glucans may soon emerge as a game-changing ally in the fight against Parkinson’s disease, offering a ray of hope for millions of patients around the world.
